387 related articles for article (PubMed ID: 32924568)
1. Impact of Fast-Acting Insulin Aspart on Glycemic Control in Patients with Type 1 Diabetes Using Intermittent-Scanning Continuous Glucose Monitoring Within a Real-World Setting: The GoBolus Study.
Danne T; Axel Schweitzer M; Keuthage W; Kipper S; Kretzschmar Y; Simon J; Wiedenmann T; Ziegler R
Diabetes Technol Ther; 2021 Mar; 23(3):203-212. PubMed ID: 32924568
[No Abstract] [Full Text] [Related]
2. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.
Akturk HK; Snell-Bergeon JK; Rewers A; Klaff LJ; Bode BW; Peters AL; Bailey TS; Garg SK
Diabetes Technol Ther; 2018 Oct; 20(10):639-647. PubMed ID: 30207748
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D
Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
[TBL] [Abstract][Full Text] [Related]
4. Glycemic control after switching to faster aspart in adults with type 1 diabetes.
Fadini GP; Boscari F; Falaguasta D; Ferretto S; Maran A; Avogaro A; Bruttomesso D
J Endocrinol Invest; 2022 Jun; 45(6):1181-1188. PubMed ID: 35103951
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes.
Beck RW; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro C; Li Z; Calhoun P
Diabetes Technol Ther; 2022 Oct; 24(10):681-696. PubMed ID: 36173235
[No Abstract] [Full Text] [Related]
6. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
Klonoff DC; Evans ML; Lane W; Kempe HP; Renard E; DeVries JH; Graungaard T; Hyseni A; Gondolf T; Battelino T
Diabetes Obes Metab; 2019 Apr; 21(4):961-967. PubMed ID: 30537180
[TBL] [Abstract][Full Text] [Related]
7. Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5.
Gorst-Rasmussen A; Sturis J; Ekelund M
Diabetes Technol Ther; 2022 Jan; 24(1):10-17. PubMed ID: 34524005
[No Abstract] [Full Text] [Related]
8. A survey of physician experience and treatment satisfaction using fast-acting insulin aspart in people with type 1 or type 2 diabetes.
Baru A; Amir S; Ekelund M; Montagnoli R; Da Rocha Fernandes JD
Postgrad Med; 2020 May; 132(4):320-327. PubMed ID: 32306819
[TBL] [Abstract][Full Text] [Related]
9. Continuous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Data from the German/Austrian Prospective Diabetes Follow-Up Registry.
Sandig D; Grimsmann J; Reinauer C; Melmer A; Zimny S; Müller-Korbsch M; Forestier N; Zeyfang A; Bramlage P; Danne T; Meissner T; Holl RW
Diabetes Technol Ther; 2020 Aug; 22(8):602-612. PubMed ID: 32522039
[No Abstract] [Full Text] [Related]
10. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
[TBL] [Abstract][Full Text] [Related]
11. Glucose control using fast-acting insulin aspart in a real-world setting: A 1-year, two-centre study in people with type 1 diabetes using continuous glucose monitoring.
Billion L; Charleer S; Verbraeken L; Sterckx M; Vangelabbeek K; De Block N; Janssen C; Van Dessel K; Dirinck E; Peiffer F; Bolsens N; Mathieu C; Gillard P; De Block C
Diabetes Obes Metab; 2021 Dec; 23(12):2716-2727. PubMed ID: 34402157
[TBL] [Abstract][Full Text] [Related]
12. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
13. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
Russell-Jones D; Bode BW; De Block C; Franek E; Heller SR; Mathieu C; Philis-Tsimikas A; Rose L; Woo VC; Østerskov AB; Graungaard T; Bergenstal RM
Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
[TBL] [Abstract][Full Text] [Related]
14. Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial.
Messer LH; Buckingham BA; Cogen F; Daniels M; Forlenza G; Jafri RZ; Mauras N; Muir A; Wadwa RP; White PC; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro CA; Li Z; Marak MC; Calhoun P; Beck RW
Diabetes Technol Ther; 2022 Oct; 24(10):712-725. PubMed ID: 36173237
[No Abstract] [Full Text] [Related]
15. Lower Glycated Hemoglobin with Real-Time Continuous Glucose Monitoring Than with Intermittently Scanned Continuous Glucose Monitoring After 1 Year: The CORRIDA LIFE Study.
Radovnická L; Hásková A; Do QD; Horová E; Navrátilová V; Mikeš O; Cihlář D; Parkin CG; Grunberger G; Prázný M; Šoupal J
Diabetes Technol Ther; 2022 Dec; 24(12):859-867. PubMed ID: 36037056
[No Abstract] [Full Text] [Related]
16. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
Buse JB; Carlson AL; Komatsu M; Mosenzon O; Rose L; Liang B; Buchholtz K; Horio H; Kadowaki T
Diabetes Obes Metab; 2018 Dec; 20(12):2885-2893. PubMed ID: 30259644
[TBL] [Abstract][Full Text] [Related]
17. Basal Insulin Degludec and Glycemic Control Compared to Aspart Via Insulin Pump in Type 1 Diabetes (BIGLEAP): A Single-Center, Open-Label, Randomized, Crossover Trial.
Lane WS; Weinrib SL; Lawrence MJ; Lane BC; Jarrett RT
Endocr Pract; 2022 Feb; 28(2):165-172. PubMed ID: 34763071
[TBL] [Abstract][Full Text] [Related]
18. A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 Diabetes.
Kruger D; Kass A; Lonier J; Pettus J; Raskin P; Salam M; Trikudanathan S; Zhou K; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro C; Li Z; Marak MC; Calhoun P; Beck RW
Diabetes Technol Ther; 2022 Oct; 24(10):697-711. PubMed ID: 36173236
[No Abstract] [Full Text] [Related]
19. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study.
Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R
Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901
[TBL] [Abstract][Full Text] [Related]
20. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
